Adverum Biotechnologies Appoints Linda Neuman, M.D. as Vice President, Clinical Development
October 02 2017 - 7:24PM
Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a leading gene therapy
company advancing novel medicines to address unmet needs in serious
rare and ocular diseases, announced today the appointment of Linda
Neuman, M.D. as vice president, clinical development. In this
newly-created position, Dr. Neuman will report to Athena
Countouriotis, M.D., senior vice president and chief medical
officer. Dr. Neuman has 15 years of experience in the biotechnology
industry and 10 years of experience in clinical practice.
“Linda has significant drug development experience and has led
multiple programs entering the clinic all the way to approval,”
said Amber Salzman, Ph.D., president and chief executive officer of
Adverum Biotechnologies. “We are excited to have Linda on board as
she brings deep clinical development and medical affairs
experience, as well as an understanding of patients through her
work as an internist. We look forward to her leadership and
execution as we advance our three lead gene therapy programs toward
the clinic.”
“I am excited to join this team of professionals driven to
advance novel gene therapies to improve treatment options for
patients,” said Linda Neuman, M.D., vice president, clinical
development of Adverum. “I was impressed by the team’s expertise
and energy, and I look forward to taking a leadership role in
shaping Adverum’s clinical development strategy as we prepare to
advance ADVM-043 into clinical development and additional compounds
in the future.”
Linda Neuman, M.D., M.B.A., has 25 years of experience in the
biotechnology industry and in clinical practice treating patients.
Most recently, Dr. Neuman served as vice president, clinical
development at Sunesis Pharmaceuticals, Inc. where she led the
filing of an Investigational New Drug application and initiated a
Phase 1b/2 clinical study in patients. Before Sunesis, she worked
with Puma Biotechnology, Inc. as senior medical director, oncology.
Previously, Dr. Neuman was medical director of oncology at Onyx
Pharmaceuticals, where she served as clinical lead on the global
product development team. Earlier in her career, Dr. Neuman held
roles of increasing responsibility at Covidien Pharmaceuticals,
Millennium Pharmaceuticals, Inc., and Schering-Plough. She began
her career in clinical practice as an internist. Dr. Neuman earned
an M.D. and B.S. in biology from Southern Illinois University. Dr.
Neuman also received an M.B.A from Indiana Wesleyan University.
On the date she commenced her employment, Adverum granted Dr.
Neuman a stock option to purchase 92,000 shares of Adverum’s common
stock pursuant to the inducement grant exception under NASDAQ Rule
5635(c)(4), as an inducement that is material to Dr. Neuman’
entering into employment with Adverum. The option will have a per
share exercise price equal to the closing sales price of Adverum’s
common stock on NASDAQ on the grant date, and will vest over four
years, subject to Dr. Neuman’s continued service with Adverum.
Pursuant to the terms of Dr. Newman’s employment with Adverum, Dr.
Newman will also be granted a restricted stock unit award to
acquire 64,000 shares of Adverum’s common stock which will vest
over four yeaers, subject to Dr. Neuman’s continued service with
Adverum.
About Adverum Biotechnologies, Inc.Adverum is a
gene therapy company advancing novel medicines that may offer
life-changing benefits to patients living with serious rare and
ocular diseases. Adverum has a robust pipeline that includes
product candidates designed to treat rare diseases alpha-1
antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as
well as wet age-related macular degeneration (wAMD). Leveraging a
next-generation adeno-associated virus (AAV)-based directed
evolution platform, Adverum generates product candidates designed
to provide durable efficacy by inducing sustained expression of a
therapeutic protein. Adverum has collaboration agreements with
Regeneron Pharmaceuticals to research, develop, and commercialize
gene therapy products for ophthalmic diseases and Editas Medicine
to explore the delivery of genome editing medicines for the
treatment of inherited retinal diseases. Adverum’s core
capabilities include clinical development and in-house
manufacturing expertise, specifically in process development and
assay development. For more information please visit
www.adverum.com.
Adverum Contact:
Leone Patterson
Chief Financial Officer
650-665-7222
lpatterson@adverum.com
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Apr 2023 to Apr 2024